MedTrace Logo

Treatment Modalities in Children and Adolescents Suffering From HDM-induced Allergic Rhinitis and/or Asthma

NCT04004351 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1531

Last updated 2019-07-05

No results posted yet for this study

Summary

Two-stage, prospective, observational, real-world study of HDM-SLIT-naïve children (aged 5-11) and adolescents (aged 12-17) consulting allergists or other specialist physicians in France for an HDM-induced allergy. Physician- and/or patient-reported data on clinical symptoms, sensitization, patient profiles, symptom burdens, patient-physician dialogue, HDM SLIT regimens, and effectiveness were recorded on inclusion, and then again 6 to 12 months after the prescription of an HDM SLIT solution.

The study's primary objective was to describe treatment modalities in children (aged from 5 to 11) and adolescents (aged from 12 to 17) with suspected HDM-induced AR or allergic asthma consulting an allergist or another specialist physician in France.

Conditions

  • Allergy

Sponsors & Collaborators

  • Monitoring Force Group

    collaborator INDUSTRY

  • Stallergenes Greer

    lead INDUSTRY

Principal Investigators

  • Bertrand Delaisi, MD · Robert Debré Hospital, Paris, France

Eligibility

Min Age
5 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-16
Primary Completion
2016-07-12
Completion
2016-07-12

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04004351 on ClinicalTrials.gov